Discovery of pyrroledione analogs as potent transient receptor potential canonical channel 5 inhibitors

A deepening understanding of the relationship between transient receptor potential canonical channel 5 (TRPC5) and chronic kidney disease (CKD), has led to the emergence of several types of TRPC5 inhibitors displaying clear therapeutic effect. Herein, we report the synthesis and biological evaluation of a series of pyrroledione TRPC5 inhibitors, culminating in the discovery of compound 16g with subtype selectivity. Compared with GFB-8438, a potent TRPC5 inhibitor (Goldfinch Bio), compound 16g showed improved inhibition of TRPC5 and enhanced protective effect against protamine sulfates (PS)-induced podocyte injury in vitro. In addition, compound 16g did not induce cell death in primary cultured hepatocytes and immortalized podocytes in a preliminary toxicity assessment, indicating its utility as a potent and safe inhibitor for studying the function of TRPC5.

Automated summary

The synthesis and biological evaluation of a series of pyrroledione TRPC5 inhibitors has led to the discovery of compound 16g with subtype selectivity, showing improved inhibition of TRPC5 and enhanced protective effect against PS-induced podocyte injury in vitro. Compound 16g also demonstrated no cell death in primary cultured hepatocytes and immortalized podocytes in a preliminary toxicity assessment, suggesting its potential as a potent and safe inhibitor for studying the function of TRPC5.